Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cancidas
2. Caspofungin
3. Caspofungin Msd
4. L 743,872
5. L 743872
6. L-743,872
7. L-743872
8. L743,872
9. L743872
10. Mk 0991
11. Mk-0991
12. Mk0991
1. Cancidas
2. Caspofungin Diacetate
3. 179463-17-3
4. Mk 0991
5. L 743872
6. Cancidas (tn)
7. Mk-0991
8. Caspofungin Acetate- Bio-x
9. Schembl149293
10. L 743873
11. Chembl4297142
12. Caspofungin Acetate (jan/usan)
13. Mfcd08141839
14. Akos025401982
15. Ac-27763
16. Bc164293
17. D02501
18. F20901
19. 463c173
Molecular Weight | 1213.4 g/mol |
---|---|
Molecular Formula | C56H96N10O19 |
Hydrogen Bond Donor Count | 18 |
Hydrogen Bond Acceptor Count | 22 |
Rotatable Bond Count | 23 |
Exact Mass | 1212.68532087 g/mol |
Monoisotopic Mass | 1212.68532087 g/mol |
Topological Polar Surface Area | 487 Ų |
Heavy Atom Count | 85 |
Formal Charge | 0 |
Complexity | 1930 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 14 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Caspofungin acetate |
Active Ingredient | Caspofungin acetate |
Dosage Form | Injectable |
Route | injection |
Strength | 70mg/vial; 50mg/vial |
Market Status | Tentative Approval |
Company | Sandoz |
2 of 2 | |
---|---|
Drug Name | Caspofungin acetate |
Active Ingredient | Caspofungin acetate |
Dosage Form | Injectable |
Route | injection |
Strength | 70mg/vial; 50mg/vial |
Market Status | Tentative Approval |
Company | Sandoz |
- Treatment of invasive candidiasis in adult or paediatric patients.
- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.
Fungal infections
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
J02AX04
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?